Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON32223
NL-OMON32223
Not yet recruiting
Phase 2

Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a Phase-II and observation study (EORTC 22042-26042) - EORTC Weber meningioma study

EORTC0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
EORTC
Enrollment
30
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
EORTC

Eligibility Criteria

Inclusion Criteria

  • •summary of protocol page 22:
  • •Adult patients in a fair condition after resection of an intracranial atypical or malignant meningioma.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Post-Operative Radiotherapy for Selected High Risk Rectal AdenocarcinomaColorectal cancerCancerColorectal
ISRCTN91411631orthern and Yorkshire Clinical Trials and Research Unit (UK)
Recruiting
Phase 1
Dose-intensified neoadjuvant radiochemotherapy for operable locally advanced NSCLC Stage III A & Bnonsmall-cell lung cancer (NSCLC)C34Malignant neoplasm of bronchus and lung
DRKS00010244niversitätsklinikum Essen35
Active, not recruiting
Phase 1
Postoperative radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC)Advanced primary resectable stage III, IVA/B head and neck squamous cell carcinoma (HNSCC)MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-002546-74-DEniversity Leipzig240
Active, not recruiting
Phase 1
Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A Phase III study
EUCTR2006-002772-17-FREuropean Organisation for Research and Treatment of Cancer86
Recruiting
Phase 3
Postoperative radiotherapy (PORT) for pathological N2 non-small cell lung cancer with adjuvant chemotherapy: a randomized phase III trial (JCOG1916, J-PORT)pathological N2 non-small cell lung cancer
JPRN-UMIN000042905Japan Clinical Oncology Group (JCOG)330